Asperuloside ameliorates dopaminergic neuron injury in Parkinson’s disease by reprogramming microglial glucose metabolism in part through the AMPK pathway to induce M2 polarization
This study investigated whether asperuloside (ASP) regulates microglial metabolic reprogramming and polarization via AMPK signaling to protect dopaminergic neurons in Parkinson’s disease (PD). In LPS-stimulated BV-2 microglia, ASP reduced pro-inflammatory cytokines (TNF-α, IL-6, IL-1β), decreased the CD86/CD206 ratio, upregulated M2 markers ( Arg1 , Chil3 , Retnla ) and enhanced the activities of SOD, CAT, and GPx. ASP shifted metabolism from glycolysis to oxidative phosphorylation (reduced ECAR/lactate, restored OCR/ATP, upregulated Ppargc1a / Nrf1 ), accompanied by increased AMPK phosphorylation and reduced NF-κB activation; these effects were partially blocked by dorsomorphin (AMPK inhibitor). Conditioned media from ASP-treated microglia improved MN9D neuronal viability, reduced apoptosis, and increased PSD95/SYP. In MPTP-treated mice, ASP improved motor function, reduced α-synuclein aggregation, increased TH + neurons, restored striatal dopamine and its metabolites (DOPAC and HVA), and decreased M1 microglia and pro-inflammatory cytokines in the substantia nigra. Collectively, these findings suggest that ASP modulates microglial metabolism and polarization, at least in part through the AMPK/NF-κB signaling, contributing to neuroprotection in PD.
Asperuloside ameliorates dopaminergic neuron injury in Parkinson’s disease by reprogramming microglial glucose metabolism in part through the AMPK pathway to induce M2 polarization. // Im Fokus Onkologie. – 2026. – DOI: 10.1007/s00221-026-07431-6. – URL: https://link.springer.com/article/10.1007/s00221-026-07431-6
(2026). Asperuloside ameliorates dopaminergic neuron injury in Parkinson’s disease by reprogramming microglial glucose metabolism in part through the AMPK pathway to induce M2 polarization. Im Fokus Onkologie. https://doi.org/10.1007/s00221-026-07431-6
“Asperuloside ameliorates dopaminergic neuron injury in Parkinson’s disease by reprogramming microglial glucose metabolism in part through the AMPK pathway to induce M2 polarization.” Im Fokus Onkologie, 2026. doi:10.1007/s00221-026-07431-6.
@article{article34886,
title = {Asperuloside ameliorates dopaminergic neuron injury in Parkinson’s disease by reprogramming microglial glucose metabolism in part through the AMPK pathway to induce M2 polarization},
journal = {Im Fokus Onkologie},
year = {2026},
doi = {10.1007/s00221-026-07431-6},
url = {https://link.springer.com/article/10.1007/s00221-026-07431-6}
}
Purpose The engineered v5.9 DNA polymerase has been reported to exhibit enhanced thermostability in loop-mediated isothermal amplification (LAMP). As an initial step toward field-deployable molecular diagnosis of giardiasis, we...
Background Polygenic risk scores for cardiovascular disease show poor agreement between methods, and most treat sex as a covariate rather than stratifying by it, despite well-documented sex differences in disease incidence and outcomes....
Communications Medicine, Published online: 19 November 2026; doi:10.1038/s43856-026-02013-7 The authors identify the mitochondrial RNA methyltransferase, NSUN4 as a potential therapeutic target in intrahepatic cholangiocarcinoma, with...
Communications Medicine, Published online: 19 November 2026; doi:10.1038/s43856-026-02009-3 People with type 2 diabetes can have too much sugar in their blood stream, which can lead to health problems. Metformin is a common medication...
Cognitive tests are commonly used to evaluate the effects of cognitive and exercise interventions in Parkinson’s disease, but their ability to distinguish genuine change from measurement variability remains insufficiently characterized....